Evolution of the Average Target: CureVac N.V.

Evolution of the Target Price: CureVac N.V.

Changes in Analyst Recommendations: CureVac N.V.

9.QNNPaMEO8QTJrgbLkZaL2TxtlHHn2CCN9I_lILi76Is.NYkHDvRKgEKPmHG-6Pr-r04-5AGjgk7YuuuAEefWpdkmuhU6g3ahZquaTw~50c424ecaa8ccc99ce4898f602e1d1ba
CUREVAC : Successful cash burn reduction Jun. 01Alphavalue
UBS Trims Price Target on CureVac to $12 From $13, Maintains Buy Rating Apr. 30 MT
CUREVAC : 2025 will be less costly Apr. 11Alphavalue
CUREVAC : The mid-term effect of pipeline pruning Feb. 21Alphavalue
CUREVAC : Licensing deal boosts bank account Dec. 12Alphavalue
CUREVAC : Positive one-off overshadows pipeline dryness Dec. 08Alphavalue
CUREVAC : Deutsche Bank reiterates its Neutral rating 24-09-02 ZD
CUREVAC : A beneficial deal 24-08-31Alphavalue
CUREVAC : Much noise at CureVac, overshadowing recent positive pipeline progress 24-08-20Alphavalue
CUREVAC : Significant cash drain in the Q1 24-05-23Alphavalue
CUREVAC : A missed opportunity 24-05-02Alphavalue
UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating 24-04-26 MT
Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4 24-04-25 MT
Kempen Upgrades CureVac to Buy From Neutral, Price Target is $10 23-12-22 MT
CUREVAC : An untrimmed pipeline becomes costly 23-11-29Alphavalue
CUREVAC : Unchanged cash drain 23-11-28Alphavalue
CUREVAC : A missed opportunity 23-08-21Alphavalue
CUREVAC : Higher losses expected in future 23-07-25Alphavalue
CUREVAC : Some glimpse of positive pipeline developments 23-06-21Alphavalue
SVB Securities Initiates CureVac at Outperform With $13 Price Target 23-06-08 MT
CUREVAC : Runway prolonged 23-05-30Alphavalue
CUREVAC : One big point despite many misses 23-05-02Alphavalue
JMP Securities Adjusts Price Target on CureVac to $24 From $34, Maintains Outperform Rating 23-04-26 MT
CUREVAC : Everything hangs on the decision of the new CEO 23-03-16Alphavalue
UBS Upgrades CureVac to Buy From Neutral, Adjusts Price Target to $18 From $8 23-01-19 MT
More recommendations

Consensus (Composite) Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Ecart obj. / dr
+55.13%
+14.06%
+19.71%
+32.48%
-0.21%
-7.46%
+21.98%
+71.66%
+31.2%
+5.64%
Average +24.42%
Weighted average by Cap. +20.11%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
3.544EUR
Average target price
5.608EUR
Spread / Average Target
+58.23%
High Price Target
10.59EUR
Spread / Highest target
+198.80%
Low Price Target
2.612EUR
Spread / Lowest Target
-26.30%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

alphavalue Martin Schnee
UBS
DEUTSCHE BANK RESEARCH Emmanuel Papadakis
Leerink Partners
Kempen
SVB Securities LLC
JMP Securities
Jefferies & Co.
BERENBERG Zhiqiang Shu
Berenberg Bank
BofA Securities
Deutsche Bank Securities
Guggenheim

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. CVAC Stock
  4. Consensus CureVac N.V.